Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients
Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients
复制标题
DOI：
10.1016/j.cyto.2015.02.019
复制
发表时间：
2015-05-01
期刊：
影响因子：
3.8
通讯作者：
Sun, Chaofeng
中科院分区：
文献类型：
--
作者：
Han, Xinyuan;Chen, Chunyan;Sun, Chaofeng
背景：成纤维细胞生长因子21（FGF-21）是一种新发现的脂肪因子，在葡萄糖和脂质代谢中发挥重要作用，并与肥胖和心血管疾病等代谢性疾病的发生有关。本研究旨在探讨血清 FGF-21 水平与心房颤动 (AF) 的关系。方法：共纳入 113 名 AF 患者和 60 名健康对照受试者。所有房颤病例均分为阵发性、持续性和永久性房颤。检测血清FGF-21、高敏C反应蛋白（hs-CRP）和其他常规生化参数的水平。结果：AF患者血清FGF-21水平显着高于对照组（250.12+/-78.48 vs. 144.15+/-56.31pg/mL，P
Background: Fibroblast growth factor 21 (FGF-21), a newly discovered adipokine, plays an important role in glucose and lipid metabolism and is associated with the development of metabolic disorders, such as obesity, and cardiovascular diseases. This study aimed to investigate the association of serum FGF-21 levels with the presence of atrial fibrillation (AF).Methods: Total 113 patients with AF and 60 healthy control subjects were enrolled. All AF cases were categorized into paroxysmal, persistent and permanent AF. Serum levels of FGF-21, high-sensitivity C-reactive protein (hs-CRP) and other routine biochemical parameters were measured.Results: Serum FGF-21 levels were significantly higher in AF patients than in controls (250.12 +/- 78.48 vs. 144.15 +/- 56.31 pg/mL, P